ClinConnect ClinConnect Logo
Search / Trial NCT06895746

Multi-omics Study in Citrin Deficiency

Launched by JOHANNES HAEBERLE · Mar 19, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Citrin Deficiency Multi Omics Biomarker Identification

ClinConnect Summary

This clinical trial is focused on understanding Citrin Deficiency (CD), a condition that affects how the body processes certain nutrients. CD can cause a range of symptoms and has different forms, some of which are more severe. Currently, there is no cure for CD, and patients usually manage their symptoms through dietary changes and regular visits to their doctors. One of the biggest challenges in finding better treatments is that we lack reliable tests (called biomarkers) that can show how severe the condition is or how well treatments are working. This study aims to find these important biomarkers by analyzing blood samples from patients with Citrin Deficiency.

The trial is currently looking for participants, including anyone diagnosed with Citrin Deficiency, regardless of age or gender. If you or someone you know has been diagnosed with this condition, you may be eligible to join the study. Participants will provide blood samples, which will help researchers learn more about the condition and potentially lead to better treatments in the future. It's an important step towards improving care for people with Citrin Deficiency.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria for patient group:
  • confirmed diagnosis of citrin deficiency
  • Exclusion Criteria for control group:
  • any metabolic disease

About Johannes Haeberle

Johannes Haeberle is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on delivering high-quality clinical trials, Haeberle emphasizes rigorous adherence to regulatory standards and ethical guidelines. The organization collaborates with a network of esteemed research institutions and healthcare professionals to facilitate the development of novel therapies and improve patient outcomes. Through a comprehensive approach to trial design, execution, and monitoring, Johannes Haeberle aims to contribute significantly to the advancement of medical science and enhance the understanding of various health conditions.

Locations

New York, New York, United States

Bristol, , United Kingdom

Taipei, , Taiwan

Kumamoto, , Japan

London, , United Kingdom

Salford, , United Kingdom

London, , United Kingdom

Birmingham, , United Kingdom

Matsumoto, Nagano, Japan

Sheffield, , United Kingdom

Chiba, , Japan

Kurume Shi, Fukuoka, Japan

Gyeongsangnam Do, , Korea, Republic Of

Saitama, Iruma, Japan

Yokohama, Kanagawa, Japan

Tokyo, Minato City, Japan

Sendai, Miyagi, Japan

Hokkaido, Sapporo, Japan

Osaka, Umeda, Japan

Yamagata City, , Japan

Taipei, , Taiwan

Manchester, Lancashire, United Kingdom

Birmingham, , United Kingdom

Yangsang, Gyeongsang, Korea, Republic Of

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported